moclobemide has been researched along with Anxiety in 12 studies
Moclobemide: A reversible inhibitor of monoamine oxidase type A; (RIMA); (see MONOAMINE OXIDASE INHIBITORS) that has antidepressive properties.
moclobemide : A member of the class of benzamides that is benzamide substituted by a chloro group at position 4 and a 2-(morpholin-4-yl)ethyl group at the nitrogen atom. It acts as a reversible monoamine oxidase inhibitor and is used in the treatment of depression.
Anxiety: Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The anxiolytic effects of aniracetam have not been proven in animals despite its clinical usefulness for post-stroke anxiety." | 7.71 | Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. ( Kurasawa, M; Nakamura, K, 2001) |
| "Moclobemide is a reversible selective inhibitor of monoamine oxidase A." | 6.68 | Moclobemide for anxiety disorders: a focus on moclobemide for panic disorder. ( Behnke, K; Bouwer, C; Tiller, JW, 1997) |
| "The anxiolytic effects of aniracetam have not been proven in animals despite its clinical usefulness for post-stroke anxiety." | 3.71 | Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. ( Kurasawa, M; Nakamura, K, 2001) |
| "Moclobemide was superior for the reduction of the subjective general anxiety (BAI) during the first 3 months of treatment, but its influence on avoidant behavior (LSAS avoidance subscale) was less pronounced." | 2.72 | Moclobemide and cognitive behavioral therapy in the treatment of social phobia. A six-month controlled study and 24 months follow up. ( Dockery, C; Horácek, J; Höschl, C; Houbová, P; Klaschka, J; Kosová, J; Pasková, B; Prasko, J; Praskova, H; Seifertová, D; Záleský, R, 2006) |
| " The efficacies between the two dosing regimens as determined by the HAM-D score and from the CGI were found not to differ significantly." | 2.68 | A comparison of the efficacy and tolerability of moclobemide given as a single daily dose or in three divided doses per day for the treatment of patients with a major depressive episode (DSM-III-R) ( Caracatsanis, A; Collier, J; Collins, C; Cramer, D; Edwards, R; Fox, K; Newburn, G; Reeves, J; Thomas, H, 1995) |
| "Moclobemide is a reversible selective inhibitor of monoamine oxidase A." | 2.68 | Moclobemide for anxiety disorders: a focus on moclobemide for panic disorder. ( Behnke, K; Bouwer, C; Tiller, JW, 1997) |
| " Side effects were assessed through the Dosage Record Emergent Symptoms at days 0, 7, 14, 30, 45, and 60." | 2.67 | Effects of moclobemide on depressive symptoms and cognitive performance in a geriatric population: a controlled comparative study versus imipramine. ( Delle Chiaie, R; Donnini, M; Gambino, C; Pancheri, P; Seripa, S; Trillo, L; Vicario, E, 1994) |
| " While clinical aspects will be presented in a subsequent review, this article focuses primarily on moclobemide's evolution, pharmacodynamic and pharmacokinetic properties." | 2.41 | Moclobemide: evolution, pharmacodynamic, and pharmacokinetic properties. ( Bonnet, U, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (58.33) | 18.2507 |
| 2000's | 5 (41.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pekiner, FN | 1 |
| Gumru, B | 1 |
| Ozbayrak, S | 1 |
| Bonnet, U | 1 |
| Prasko, J | 1 |
| Dockery, C | 1 |
| Horácek, J | 1 |
| Houbová, P | 1 |
| Kosová, J | 1 |
| Klaschka, J | 1 |
| Pasková, B | 1 |
| Praskova, H | 1 |
| Seifertová, D | 1 |
| Záleský, R | 1 |
| Höschl, C | 1 |
| Koval'chuk, VV | 1 |
| Newburn, G | 1 |
| Edwards, R | 1 |
| Thomas, H | 1 |
| Collier, J | 1 |
| Fox, K | 1 |
| Collins, C | 1 |
| Cramer, D | 1 |
| Reeves, J | 1 |
| Caracatsanis, A | 1 |
| Pancheri, P | 1 |
| Delle Chiaie, R | 1 |
| Donnini, M | 1 |
| Seripa, S | 1 |
| Gambino, C | 1 |
| Vicario, E | 1 |
| Trillo, L | 1 |
| Griebel, G | 1 |
| Perrault, G | 1 |
| Sanger, DJ | 1 |
| Tiller, JW | 1 |
| Bouwer, C | 1 |
| Behnke, K | 1 |
| Eroğlu, L | 1 |
| Güven, O | 1 |
| Iakovlev, VA | 1 |
| Nakamura, K | 1 |
| Kurasawa, M | 1 |
1 review available for moclobemide and Anxiety
| Article | Year |
|---|---|
Moclobemide: evolution, pharmacodynamic, and pharmacokinetic properties.
Topics: Animals; Antidepressive Agents; Anxiety; Cognition Disorders; Depression; Disease Models, Animal; Dr | 2002 |
6 trials available for moclobemide and Anxiety
| Article | Year |
|---|---|
Efficacy of moclobemide in burning mouth syndrome: a nonrandomized, open-label study.
Topics: Analysis of Variance; Antidepressive Agents; Anxiety; Burning Mouth Syndrome; Case-Control Studies; | 2008 |
Moclobemide and cognitive behavioral therapy in the treatment of social phobia. A six-month controlled study and 24 months follow up.
Topics: Adolescent; Adult; Anxiety; Cognitive Behavioral Therapy; Combined Modality Therapy; Female; Follow- | 2006 |
[Pharmacologic correction of psycho-emotive disorders in the rehabilitation of patients after removal of brain tumors].
Topics: Adult; Alprazolam; Amitriptyline; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Brain Neoplas | 2007 |
A comparison of the efficacy and tolerability of moclobemide given as a single daily dose or in three divided doses per day for the treatment of patients with a major depressive episode (DSM-III-R)
Topics: Adult; Antidepressive Agents; Anxiety; Benzamides; Depressive Disorder; Double-Blind Method; Female; | 1995 |
Effects of moclobemide on depressive symptoms and cognitive performance in a geriatric population: a controlled comparative study versus imipramine.
Topics: Aged; Antidepressive Agents; Anxiety; Benzamides; Cognition; Depressive Disorder; Double-Blind Metho | 1994 |
Moclobemide for anxiety disorders: a focus on moclobemide for panic disorder.
Topics: Adult; Anxiety; Benzamides; Blood Pressure; Female; Fluoxetine; Humans; Male; Moclobemide; Monoamine | 1997 |
5 other studies available for moclobemide and Anxiety
| Article | Year |
|---|---|
Behavioural profiles of the reversible monoamine-oxidase-A inhibitors befloxatone and moclobemide in an experimental model for screening anxiolytic and anti-panic drugs.
Topics: Animals; Anxiety; Avoidance Learning; Benzamides; Disease Models, Animal; Dose-Response Relationship | 1997 |
The effects of moclobemide on the yohimbine-induced anxiogenic action in the elevated plus-maze.
Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Anti-Anxiety Agents; | 1998 |
[Aurorix--an antidepressant with a wide spectrum of action].
Topics: Antidepressive Agents; Anxiety; Benzamides; Contraindications; Depression; Dose-Response Relationshi | 1998 |
[Various forms of risk factors of antidepressive agents for influencing sexual functions. Moclobemid is first choice for the therapy of sexually active patients with depression].
Topics: Antidepressive Agents; Anxiety; Benzamides; Depression; Depressive Disorder; Female; Humans; Male; M | 1999 |
Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Bro | 2001 |